There are currently 161 active clinical trials seeking participants for Hypertension research studies. The states with the highest number of trials for Hypertension participants are California, Florida, Texas and Ontario.
Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks
NCT03374215
Recruiting
Background: The adrenal gland makes the hormone aldosterone. This helps regulate blood pressure. An adrenal gland tumor that makes too much aldosterone can cause high blood pressure and low potassium. The cause of these tumors is unknown, but sometimes they are inherited. Objective: To study the genes that may cause primary aldosteronism in Black individuals. Eligibility: People ages 18-70 who: Are Black, African American, or of Caribbean descent And have difficult to control blood pressu... Read More
Gender:
ALL
Ages:
Between 7 years and 70 years
Trial Updated:
07/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Adrenal Gland Neoplasm, Hypertension, Bone Diseases, Metabolic, Cardiovascular Disease, Hyperinsulinemia
Register for Updates
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
NCT05331144
Recruiting
The purpose of this study is to determine if intensive lowering of systolic blood pressure (SBP), using FDA approved medications (antihypertensive), reduces Alzheimer's Disease pathology (i.e., excessive brain amyloid and tau protein deposition) in older adults at high risk for memory decline or dementia.
Gender:
ALL
Ages:
Between 60 years and 85 years
Trial Updated:
07/31/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Dementia
Register for Updates
Sleep Restriction and Parental History of Hypertension
NCT06482814
Recruiting
The purpose of this study is to research the effects of partial sleep deprivation (sleep restriction) in a group of individuals whose parents have high blood pressure compared to a group of individuals whose parents have normal blood pressure.
Gender:
ALL
Ages:
Between 18 years and 35 years
Trial Updated:
07/30/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Hypertension
Register for Updates
WEAVE NM: Heart Health and Nutrition for Life
NCT07074145
Recruiting
WEAVE NM (Wide Engagement for Assessing Vaccine Equity in New Mexico) is a community-based research initiative working to improve health outcomes in underserved populations, with a current focus on hypertension and food justice. The project centers on the lived experiences of Native American, African American, Hispanic/Latino, and Asian American residents in Albuquerque's International District and South Valley. With guidance from community voices and ongoing collaboration with local organizatio... Read More
Gender:
ALL
Ages:
Between 18 years and 84 years
Trial Updated:
07/28/2025
Locations: First Nations Community HealthSource, Albuquerque, New Mexico
Conditions: Hypertension
Register for Updates
A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473
Recruiting
This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this combination to a placebo version of vicadrostat with empagliflozin. Participants are put into 2 gro... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Pinnacle Research Group, LLC, Anniston, Alabama +969 locations
Conditions: Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Register for Updates
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT06059638
Recruiting
A prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel atrioventricular interval modulation (AVIM) algorithm downloaded into a dual-chamber Medtronic Astra/Azure pacemaker.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: HonorHealth, Scottsdale, Arizona +72 locations
Conditions: Hypertension, Hypertension, Systolic, Hypertension, Essential
Register for Updates
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
NCT05198674
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama +99 locations
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Register for Updates
A Mobile Health (mHealth) Strategy for Improving Blood Pressure Control Among Adult Hypertensive African Americans
NCT06078540
Recruiting
The purpose of this study is to test the proof-of-concept for adding a novel mHealth application, USeeBP, to the established UChicago Medicine Ambulatory Medicine Remote-Patient Monitoring (UCM-RPM) Hypertension Management Program in a population of African American adults with poorly controlled hypertension.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/23/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Hypertension, Blood Pressure
Register for Updates
Addressing Barriers to Achieving Cardiometabolic Disorders Prevention and Treatment Goals for PLWH in the SE US
NCT05129345
Recruiting
This study has 3 aims. Aim 1: Identify social determinants of cardiometabolic health and determine facilitators and modifiable barriers in achieving treatment goals. Aim 2: Assess PLWH knowledge, skills, and confidence for self-management of cardiometabolic disorders. Aim 3: Tailor a self-management support and education intervention with stakeholder input to address barriers to achieving treatment goals for cardiometabolic disorders in PLWH at the study sites.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Duke University - Charlotte Study Sites, Charlotte, North Carolina +1 locations
Conditions: Hypertension, Dyslipidemias, Type 2 Diabetes, HIV-1-infection
Register for Updates
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422
Recruiting
The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a framework to evaluate the safety and efficacy of orforglipron for the treatment of hypertension in participants with obesity or overweight.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Elite Clinical Studies, LLC, Phoenix, Arizona +100 locations
Conditions: Hypertension
Register for Updates
A Study of LY3971297 in Healthy Participants
NCT06148272
Recruiting
The purpose of this study is to measure side effects of LY3971297 injection administered under the skin in healthy participants and obese participants with high blood pressure (BP). Blood tests will be performed to check how much LY3971297 gets into the bloodstream and how long it takes the body to eliminate it. This is a 7-part study. The study duration will be approximately 60 days for Parts A and F, and approximately 90 days for Parts B, C, D, E, and G.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/22/2025
Locations: CenExel ACT, Anaheim, California +5 locations
Conditions: Healthy, Obesity, Hypertension
Register for Updates
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435
Recruiting
GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Elite Clinical Studies, LLC, Phoenix, Arizona +100 locations
Conditions: Hypertension, Overweight or Obesity
Register for Updates